267 filings
8-K
BXRX
Baudax Bio, Inc.
28 Feb 24
Bankruptcy or Receivership
6:15am
25-NSE
The Nasdaq Stock Market LLC
15 Feb 24
Exchange delisting
8:53am
8-K
BXRX
Baudax Bio, Inc.
12 Dec 23
Other Events
9:52pm
424B3
BXRX
Baudax Bio, Inc.
22 Nov 23
Prospectus supplement
4:58pm
10-Q
2023 Q3
BXRX
Baudax Bio, Inc.
Quarterly report
20 Nov 23
5:28pm
NT 10-Q
2ioog 7a1lyfw4
15 Nov 23
Notice of late quarterly filing
5:25pm
8-K
20l 6qkfhbi
15 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
bki9omkpyxi2ixoxa
25 Oct 23
Changes in Registrant's Certifying Accountant
7:57am
8-K
c8cs 2lw1li2sjl9
13 Oct 23
Submission of Matters to a Vote of Security Holders
7:00am
DEFA14A
12wkgjs
10 Oct 23
Additional proxy soliciting materials
7:00am
8-K
6c1g6lm3z95gz9nw
6 Oct 23
Departure of Directors or Certain Officers
8:00am
8-K
0feh jjq32lt00qlj
29 Sep 23
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
7:01am
EFFECT
sllqd
26 Sep 23
Notice of effectiveness
12:15am
EFFECT
jiw0mc he6ntnrjb4
26 Sep 23
Notice of effectiveness
12:15am
CORRESP
vxecyr7
21 Sep 23
Correspondence with SEC
12:00am
CORRESP
xypczkvyw 8506i
21 Sep 23
Correspondence with SEC
12:00am
UPLOAD
r2dembm6dka wth2i4
13 Sep 23
Letter from SEC
12:00am